scholarly journals Real-world Effectiveness and Safety of Direct-acting Antiviral Agents in Patients with Chronic Hepatitis C Genotype 2 Infection: Korean Multicenter Study

2021 ◽  
Vol 36 (21) ◽  
Author(s):  
Yeo Wool Kang ◽  
Yang Hyun Baek ◽  
Sung Wook Lee ◽  
Sung-Jae Park ◽  
Jun Sik Yoon ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Multicenter Study ◽  
Real World ◽  
Antiviral Agents ◽  
Direct Acting Antiviral ◽  
Genotype 2 ◽  
Direct Acting ◽  
Direct Acting Antiviral Agents

scholarly journals Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data

2020 ◽  
Vol 53 (4) ◽  
pp. 569-577 ◽  
Author(s):  
Chun-Ming Hong ◽  
Chen-Hua Liu ◽  
Tung-Hung Su ◽  
Hung-Chih Yang ◽  
Pei-Jer Chen ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Real World ◽  
Antiviral Agents ◽  
Real World Data ◽  
World Data ◽  
Direct Acting Antiviral ◽  
Direct Acting ◽  
Direct Acting Antiviral Agents

scholarly journals Dynamic Changes of the Frequency of Classic and Inflammatory Monocytes Subsets and Natural Killer Cells in Chronic Hepatitis C Patients Treated by Direct-Acting Antiviral Agents

2017 ◽  
Vol 2017 ◽  
pp. 1-8 ◽  
Author(s):  
Gang Ning ◽  
Yi-ting Li ◽  
You-ming Chen ◽  
Ying Zhang ◽  
Ying-fu Zeng ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Nk Cells ◽  
Chronic Hepatitis C ◽  
Antiviral Agents ◽  
Healthy Controls ◽  
Direct Acting Antiviral ◽  
Inflammatory Monocytes ◽  
Direct Acting ◽  
Direct Acting Antiviral Agents

Objective. Up to now, little was known about the immunological changes of chronic hepatitis C (CHC) patients treated with direct-acting antiviral agents (DAAs); we try to explore the effect of DAAs on the frequency of monocytes, NK cells, and cytokines that promote their activation. Methods. 15 treatment-naive CHC patients and 10 healthy controls were recruited. Patients were examined before DAAs therapy (0 w) and at week 4 (4 w) and week 12 (12 w) of therapy. Percentage of monocytes and NK cells of the peripheral blood was analyzed by flow cytometry. Serum cytokines IL-12, IL-18, CXCL10, CXCL11, sCD14, and sCD163 were measured by enzyme linked immunosorbent assay. Results. The frequency of CD3–CD16+CD56+ NK cells and classic CD14++CD16− monocytes decreased, while CD14+CD16+ monocytes and cytokines IL-12, IL-18, CXCL10, CXCL11, sCD14, and sCD163 increased at 0 w compared to healthy controls. During DAAs treatment, the decreased NK cells and classic monocytes gradually increased to normal levels; the increased inflammatory monocytes and cytokines IL-12 and CXCL11 decreased to normal levels, but the increased cytokines IL-18, CXCL10, sCD14, and sCD163 still remained at high levels at 12 w though they decreased rapidly from 0 w. Conclusion. Our results showed that DAAs treatment attenuated the activation of monocytes and NK cells in CHC patients. Trial registration number is NCT03063723.

Sign in / Sign up

Export Citation Format

Share Document